{"disease":{"id":"nsclc-nonsquamous","name":"nsclc nonsquamous"},"drugs":{"marketed":[{"drug_id":"pembrolizumab","indication_name":"NSCLC (nonsquamous)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."},{"drug_id":"pembrolizumab","indication_name":"NSCLC (nonsquamous)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Keytruda","generic_name":"pembrolizumab","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"PD-1 receptor","drug_class":"Monoclonal antibody; PD-1 inhibitor","quality_score":98,"revenue":"29500","mechanism":"Pembrolizumab blocks PD-1 receptor, releasing immune inhibition and enhancing anti-tumor T-cell response."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"pembrolizumab","guideline_body":"FDA label","recommendation":"In combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null},{"drug_id":"pembrolizumab","guideline_body":"FDA label","recommendation":"In combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}